Zevra Therapeutics (NASDAQ:ZVRA) Given Sell (D+) Rating at Weiss Ratings

Weiss Ratings reiterated their sell (d+) rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a report issued on Tuesday morning,Weiss Ratings reports.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright began coverage on shares of Zevra Therapeutics in a research report on Wednesday, July 2nd. They set a “buy” rating and a $26.00 target price on the stock. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday. Cantor Fitzgerald lifted their target price on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Thursday, July 10th. Finally, Zacks Research cut shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $24.00.

Zevra Therapeutics Price Performance

ZVRA stock opened at $10.49 on Tuesday. The company has a market capitalization of $588.80 million, a P/E ratio of -49.95 and a beta of 1.49. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85. Zevra Therapeutics has a 52-week low of $6.19 and a 52-week high of $13.16. The business has a 50-day simple moving average of $9.37 and a two-hundred day simple moving average of $9.12.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($1.49). The company had revenue of $25.88 million for the quarter, compared to analyst estimates of $22.49 million. Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 112.40%. Research analysts expect that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Neil F. Mcfarlane sold 19,500 shares of Zevra Therapeutics stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $10.82, for a total value of $210,990.00. Following the completion of the transaction, the chief executive officer directly owned 222,016 shares in the company, valued at approximately $2,402,213.12. The trade was a 8.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John B. Bode acquired 5,000 shares of Zevra Therapeutics stock in a transaction that occurred on Tuesday, August 19th. The stock was acquired at an average price of $9.16 per share, with a total value of $45,800.00. Following the completion of the purchase, the director directly owned 45,000 shares in the company, valued at $412,200. This represents a 12.50% increase in their position. The disclosure for this purchase can be found here. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its stake in Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after buying an additional 8,552 shares in the last quarter. Rubric Capital Management LP grew its stake in Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after buying an additional 740,584 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Zevra Therapeutics by 1,240.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 42,950 shares of the company’s stock valued at $378,000 after buying an additional 39,746 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Zevra Therapeutics by 150.4% in the second quarter. Bank of America Corp DE now owns 223,852 shares of the company’s stock worth $1,972,000 after purchasing an additional 134,437 shares during the period. Finally, Adage Capital Partners GP L.L.C. raised its position in shares of Zevra Therapeutics by 15.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after buying an additional 550,000 shares in the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.